Published in Br J Pharmacol on March 31, 2008
Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology (2009) 1.19
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Prevention of stress-impaired fear extinction through neuropeptide s action in the lateral amygdala. Neuropsychopharmacology (2012) 1.07
Identification of functional differences between recombinant human α and β cardiac myosin motors. Cell Mol Life Sci (2012) 1.06
Stress-related neuropeptides and addictive behaviors: beyond the usual suspects. Neuron (2012) 1.06
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Activation of neuropeptide S-expressing neurons in the locus coeruleus by corticotropin-releasing factor. J Physiol (2012) 0.98
Behavioral phenotyping of neuropeptide S receptor knockout mice. Behav Brain Res (2009) 0.97
Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology (2010) 0.97
Neuropeptide-S (NPS) receptor genotype modulates basolateral amygdala responsiveness to aversive stimuli. Neuropsychopharmacology (2011) 0.94
Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther (2009) 0.94
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. J Med Chem (2009) 0.92
Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology (2010) 0.90
Hypothalamic neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl) (2012) 0.88
Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity. Bioorg Med Chem Lett (2008) 0.87
Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem (2010) 0.86
Transcriptomic identification of starfish neuropeptide precursors yields new insights into neuropeptide evolution. Open Biol (2016) 0.84
Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.84
Antagonism of the neuropeptide S receptor with RTI-118 decreases cocaine self-administration and cocaine-seeking behavior in rats. Pharmacol Biochem Behav (2012) 0.83
Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines as antagonists of the Neuropeptide S Receptor. ACS Chem Neurosci (2010) 0.82
Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br J Pharmacol (2009) 0.82
Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801. Neuropharmacology (2009) 0.82
Intraventricular administration of neuropeptide S has reward-like effects. Eur J Pharmacol (2011) 0.81
Identification of a role for the ventral hippocampus in neuropeptide S-elicited anxiolysis. PLoS One (2013) 0.81
In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. Pharmacol Res Perspect (2015) 0.80
Identification of neuropeptide S antagonists: structure-activity relationship studies, X-ray crystallography, and in vivo evaluation. ACS Chem Neurosci (2014) 0.79
Nuance and behavioral cogency: How the Visible Burrow System inspired the Stress-Alternatives Model and conceptualization of the continuum of anxiety. Physiol Behav (2015) 0.79
The role of neuropeptide S and neuropeptide S receptor 1 in regulation of respiratory function in mice. Peptides (2010) 0.79
Neuropeptide S-mediated facilitation of synaptic transmission enforces subthreshold theta oscillations within the lateral amygdala. PLoS One (2011) 0.79
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiol Dis (2014) 0.78
Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues. J Biol Chem (2016) 0.77
Neuronal expression of the human neuropeptide S receptor NPSR1 identifies NPS-induced calcium signaling pathways. PLoS One (2015) 0.76
Anti-aggressive effects of neuropeptide S independent of anxiolysis in male rats. Front Behav Neurosci (2014) 0.76
Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation. Psychopharmacology (Berl) (2012) 0.76
Sedative-hypnotic Effect of Ash of Silver in Mice: A Reverse Pharmacological Study. J Tradit Complement Med (2014) 0.75
Neuropeptide S differently modulates alcohol-related behaviors in alcohol-preferring and non-preferring rats. Psychopharmacology (Berl) (2016) 0.75
Neuropeptide S reduces duodenal bicarbonate secretion and ethanol-induced increases in duodenal motility in rats. PLoS One (2017) 0.75
A single-nucleotide polymorphism of human neuropeptide s gene originated from Europe shows decreased bioactivity. PLoS One (2013) 0.75
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods (1985) 9.05
Characterization of a common susceptibility locus for asthma-related traits. Science (2004) 4.05
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 3.61
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev (2003) 2.93
Genome-wide association of sleep and circadian phenotypes. BMC Med Genet (2007) 2.05
Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol (2007) 1.95
Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther (2005) 1.81
Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods (1986) 1.74
The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev (2006) 1.70
Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology (2006) 1.49
Expression and function of NPSR1/GPRA in the lung before and after induction of asthma-like disease. Am J Physiol Lung Cell Mol Physiol (2006) 1.37
Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I. J Biol Chem (2006) 1.32
Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology (2007) 1.24
Peptide S is a novel potent inhibitor of voluntary and fast-induced food intake in rats. Biochem Biophys Res Commun (2005) 1.23
Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.23
The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology (Berl) (2000) 1.13
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Stress-induced hyperthermia and anxiety: pharmacological validation. Eur J Pharmacol (2003) 1.13
Sex differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors. Acta Physiol (Oxf) (2007) 1.05
Neuropeptide S and G protein-coupled receptor 154 modulate macrophage immune responses. Hum Mol Genet (2006) 1.02
Centrally administered neuropeptide S activates orexin-containing neurons in the hypothalamus and stimulates feeding in rats. Endocrine (2006) 1.01
Differential effects of central nervous system depressants in long-sleep and short-sleep mice. J Pharmacol Exp Ther (1986) 0.96
Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.94
Anorexigenic effects of central neuropeptide S involve the hypothalamus in chicks (Gallus gallus). Comp Biochem Physiol A Mol Integr Physiol (2007) 0.93
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci (2003) 0.92
Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol (2002) 0.91
[Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. J Pharmacol Exp Ther (2002) 0.89
Caffeine treatment regulates neuropeptide S system expression in the rat brain. Neurosci Lett (2006) 0.86
Neuropeptide S: a novel activating anxiolytic? Neuron (2004) 0.86
Nicotine treatment regulates neuropeptide S system expression in the rat brain. Neurotoxicology (2007) 0.84
GABAA-benzodiazepine receptor complex ligands and stress-induced hyperthermia in singly housed mice. Pharmacol Biochem Behav (2002) 0.83
Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 8.11
A developmental and genetic classification for malformations of cortical development. Neurology (2005) 3.50
Terminology and classification of the cortical dysplasias. Neurology (2004) 2.99
Classification system for malformations of cortical development: update 2001. Neurology (2001) 2.59
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Pharmacology of angiotensin. Pharmacol Rev (1974) 2.25
Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain (2006) 2.00
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci (1988) 1.83
Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology (1990) 1.78
Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology (2008) 1.74
GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology (2012) 1.67
Syndromes of bilateral symmetrical polymicrogyria. AJNR Am J Neuroradiol (2000) 1.66
Congenital bilateral perisylvian syndrome: study of 31 patients. The CBPS Multicenter Collaborative Study. Lancet (1993) 1.65
Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium. Eur J Pharmacol (1985) 1.64
Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate results. Epilepsia (2001) 1.62
Protocadherin 19 mutations in girls with infantile-onset epilepsy. Neurology (2010) 1.59
Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology (2005) 1.57
Selective agonists for substance P and neurokinin receptors. Neuropeptides (1987) 1.51
Pharmacological receptors for substance P and neurokinins. Life Sci (1987) 1.50
Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol (1992) 1.50
Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea. Br J Pharmacol (1988) 1.49
Characterization of mutations in the gene doublecortin in patients with double cortex syndrome. Ann Neurol (1999) 1.47
Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol (1983) 1.47
Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today (1996) 1.45
Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology (2003) 1.45
De novo formation of vascular receptors for bradykinin. Can J Physiol Pharmacol (1978) 1.45
X-linked malformations of neuronal migration. Neurology (1996) 1.42
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
Facial hemangioma and cerebral corticovascular dysplasia: a syndrome associated with epilepsy. Neurology (2003) 1.39
An analysis of the negative inotropic action of somatostatin. Br J Pharmacol (1979) 1.37
Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol (1977) 1.37
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med (1995) 1.34
The actions of kinin antagonists on B1 and B2 receptor systems. Eur J Pharmacol (1986) 1.31
Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol (2007) 1.30
Competitive antagonists discriminate between NK2 tachykinin receptor subtypes. Br J Pharmacol (1990) 1.26
Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med (2000) 1.24
Different receptors are involved in the endothelium-mediated relaxation and the smooth muscle contraction of the rabbit pulmonary artery in response to substance P and related neurokinins. Eur J Pharmacol (1986) 1.24
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Receptors for substance P. I. The pharmacological preparations. Eur J Pharmacol (1984) 1.24
Relative potencies of neurokinins in guinea pig trachea and human bronchus. Eur J Pharmacol (1987) 1.22
Band heterotopia: correlation of outcome with magnetic resonance imaging parameters. Ann Neurol (1994) 1.22
Clinical and molecular characteristics of 1qter microdeletion syndrome: delineating a critical region for corpus callosum agenesis/hypogenesis. J Med Genet (2008) 1.20
Brain auditory activation measured by near-infrared spectroscopy (NIRS) in neonates. Pediatr Res (2001) 1.18
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Familial periventricular heterotopia: missense and distal truncating mutations of the FLN1 gene. Neurology (2002) 1.18
Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun (1992) 1.17
Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) (1999) 1.17
Intracellular levels of the LIS1 protein correlate with clinical and neuroradiological findings in patients with classical lissencephaly. Ann Neurol (1999) 1.16
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth (2009) 1.15
Characterization of neurokinin receptors in various isolated organs by the use of selective agonists. Life Sci (1987) 1.14
Mutations in the oligophrenin-1 gene (OPHN1) cause X linked congenital cerebellar hypoplasia. J Med Genet (2003) 1.14
Bilateral posterior periventricular nodular heterotopia: a recognizable cortical malformation with a spectrum of associated brain abnormalities. AJNR Am J Neuroradiol (2013) 1.14
Familial perisylvian polymicrogyria: a new familial syndrome of cortical maldevelopment. Ann Neurol (2000) 1.13
Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry (2002) 1.13
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol (2001) 1.12
Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J Med Chem (1999) 1.11
Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun (1991) 1.10
Biological activity of N-terminal fragments of calcitonin gene-related peptide. Eur J Pharmacol (1990) 1.10
Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol (1984) 1.10
Human doublecortin (DCX) and the homologous gene in mouse encode a putative Ca2+-dependent signaling protein which is mutated in human X-linked neuronal migration defects. Hum Mol Genet (1998) 1.09
High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int (1995) 1.09
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.08
Cardiovascular actions of kinins in the rabbit. Can J Physiol Pharmacol (1979) 1.08
The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. Eur J Pharmacol (1987) 1.08
BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol (2000) 1.08
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol (1989) 1.07
Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br J Pharmacol (1999) 1.06
Peptides and the human colon: an in vitro pharmacological study. Can J Physiol Pharmacol (1981) 1.05
Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension (1998) 1.05
Kinin receptors in experimental inflammation. Can J Physiol Pharmacol (1980) 1.05
Genetic and neuroradiological heterogeneity of double cortex syndrome. Ann Neurol (2000) 1.05
Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta (2009) 1.05
Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J Med Chem (1997) 1.05
Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol (1998) 1.04
Mosaic mutations of the LIS1 gene cause subcortical band heterotopia. Neurology (2003) 1.04
Abnormal corticomuscular and intermuscular coupling in high-frequency rhythmic myoclonus. Brain (2003) 1.04
Pressor action of beta blocking agents in rats. Can J Physiol Pharmacol (1970) 1.03